These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 31006923)

  • 21. Fetal fraction-based risk algorithm for non-invasive prenatal testing: screening for trisomies 13 and 18 and triploidy in women with low cell-free fetal DNA.
    McKanna T; Ryan A; Krinshpun S; Kareht S; Marchand K; Grabarits C; Ali M; McElheny A; Gardiner K; LeChien K; Hsu M; Saltzman D; Stosic M; Martin K; Benn P
    Ultrasound Obstet Gynecol; 2019 Jan; 53(1):73-79. PubMed ID: 30014528
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cell-free DNA screening for trisomies 21, 18, and 13 in pregnancies at low and high risk for aneuploidy with genetic confirmation.
    Dar P; Jacobsson B; MacPherson C; Egbert M; Malone F; Wapner RJ; Roman AS; Khalil A; Faro R; Madankumar R; Edwards L; Haeri S; Silver R; Vohra N; Hyett J; Clunie G; Demko Z; Martin K; Rabinowitz M; Flood K; Carlsson Y; Doulaveris G; Malone C; Hallingstrom M; Klugman S; Clifton R; Kao C; Hakonarson H; Norton ME
    Am J Obstet Gynecol; 2022 Aug; 227(2):259.e1-259.e14. PubMed ID: 35085538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contingent prenatal screening for frequent aneuploidies with cell-free fetal DNA analysis.
    Torres Aguilar MR; Carrasco Salas P; Santos Rosa C; Bueno Rodríguez G; Martínez-Bonet E; Carreto Alba P; León-Justel A; Granell Escobar MR
    Taiwan J Obstet Gynecol; 2021 Jul; 60(4):745-751. PubMed ID: 34247818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Massively Parallel Sequencing (MPS) of Cell-Free Fetal DNA (cffDNA) for Trisomies 21, 18, and 13 in Twin Pregnancies.
    Du E; Feng C; Cao Y; Yao Y; Lu J; Zhang Y
    Twin Res Hum Genet; 2017 Jun; 20(3):242-249. PubMed ID: 28485265
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Replacing the combined test by cell-free DNA testing in screening for trisomies 21, 18 and 13: impact on the diagnosis of other chromosomal abnormalities.
    Syngelaki A; Pergament E; Homfray T; Akolekar R; Nicolaides KH
    Fetal Diagn Ther; 2014; 35(3):174-84. PubMed ID: 24525399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment and Clinical Utility of a Non-Next-Generation Sequencing-Based Non-Invasive Prenatal Testing Technology.
    Gormus U; Chaubey A; Shenoy S; Wong YW; Chan LY; Choo BP; Oraha L; Gousseva A; Persson F; Prensky L; Chin E; Hegde M
    Curr Issues Mol Biol; 2021 Aug; 43(2):958-964. PubMed ID: 34449543
    [No Abstract]   [Full Text] [Related]  

  • 27. Prenatal reflex DNA screening for trisomy 21, 18 and 13.
    Wald NJ
    Expert Rev Mol Diagn; 2018 May; 18(5):399-401. PubMed ID: 29633889
    [No Abstract]   [Full Text] [Related]  

  • 28. DNA sequencing versus standard prenatal aneuploidy screening.
    Bianchi DW; Parker RL; Wentworth J; Madankumar R; Saffer C; Das AF; Craig JA; Chudova DI; Devers PL; Jones KW; Oliver K; Rava RP; Sehnert AJ;
    N Engl J Med; 2014 Feb; 370(9):799-808. PubMed ID: 24571752
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective first-trimester screening for trisomies by cell-free DNA testing of maternal blood in twin pregnancy.
    Sarno L; Revello R; Hanson E; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Jun; 47(6):705-11. PubMed ID: 26970114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. False-positive rates in screening for trisomies 18 and 13: a comparison between first-trimester combined screening and a cfDNA-based approach.
    Kagan KO; Sonek J; Sroka A; Abele H; Wagner P; Prodan N; Hoopmann M
    Arch Gynecol Obstet; 2019 Feb; 299(2):431-437. PubMed ID: 30519751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Combining Effects of Cell-Free Circulating Tumor DNA of Breast Tumor to the Noninvasive Prenatal Testing Results: A Simulating Investigation.
    Cai YH; Yao GY; Chen LJ; Gan HY; Ye CS; Yang XX
    DNA Cell Biol; 2018 Jul; 37(7):626-633. PubMed ID: 29957029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contingent cfDNA Screening Implementation: Increasing Diagnostic Accuracy and Reducing Invasive Testing - 6 Years' Results in a Single Center.
    Cubo AM; Huélamo M; Martín-Seisdedos MC; Hernández-Hernández E; Lapresa-Alcalde MV; Rodríguez-Martín MO; Doyague MJ; Sayagués JM
    Fetal Diagn Ther; 2022; 49(3):103-113. PubMed ID: 35259749
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Payer decision making for next-generation sequencing-based genetic tests: insights from cell-free DNA prenatal screening.
    Dervan AP; Deverka PA; Trosman JR; Weldon CB; Douglas MP; Phillips KA
    Genet Med; 2017 May; 19(5):559-567. PubMed ID: 27657682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical significance of non-invasive prenatal testing in preventing birth defects].
    Zhang W; Li S; Tang P; Wang J; Gu S
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2020 Oct; 37(10):1061-1064. PubMed ID: 32924101
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytogenomic results following high-chance non-invasive prenatal testing: a UK national audit.
    Togneri FS; Allen SK; Mann K; Holgado E; Morgan S
    Genet Res (Camb); 2020 Sep; 102():e7. PubMed ID: 32867862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimizing Fetal Aneuploidy Screening in an Austere Military Clinical Environment: A Prenatal Cost Comparison.
    Burrus AD; Shaw-Williams MM; Thagard AS
    Mil Med; 2021 Jan; 186(3-4):e410-e414. PubMed ID: 33181837
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [MODELS OF CLINICAL IMPLEMENTATION OF CELL FREE FETAL DNA IN THE MATERNAL SERUM SCREENING TEST-ANALYSIS].
    Yankova M; Chaveeva P; Stratieva V
    Akush Ginekol (Sofiia); 2015; 54(7):15-21. PubMed ID: 27025103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Application of non-invasive prenatal testing for the screening of fetal chromosomal abnormalities in 12 085 cases].
    Wang L; Zhou C; Hu Y; Jin Y; Liu X
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2020 Oct; 37(10):1069-1073. PubMed ID: 32924103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cell-free DNA analysis in maternal blood: comparing genome-wide versus targeted approach as a first-line screening test.
    de Wergifosse S; Bevilacqua E; Mezela I; El Haddad S; Gounongbe C; de Marchin J; Maggi V; Conotte S; Badr DA; Fils JF; Guizani M; Jani JC
    J Matern Fetal Neonatal Med; 2021 Nov; 34(21):3552-3561. PubMed ID: 31722585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cell-Free DNA Analysis in Maternal Blood: Differences in Estimates between Laboratories with Different Methodologies Using a Propensity Score Approach.
    Bevilacqua E; Jani JC; Letourneau A; Duiella SF; Kleinfinger P; Lohmann L; Resta S; Cos Sanchez T; Fils JF; Mirra M; Benachi A; Costa JM
    Fetal Diagn Ther; 2019; 45(5):302-311. PubMed ID: 29898450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.